# colorectal cancer - gpt-5.6-luna

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: OpenAI / gpt-5.6-luna
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 55818
- Completion tokens: 26323
- Reasoning tokens: 0
- Total tokens: 82141
- API requests reported: 5
- Elapsed seconds: 224.811
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: OpenAI

---
## Data-quality and evidence status

This is a prognostic, not differential-expression, analysis: HR > 1 indicates higher estimated hazard and HR < 1 indicates lower estimated hazard in the **input/uploaded** cohort. The statistical evidence is substantial but technically requires caution:

- The ledger contains **100 unique genes represented by 209 retained rows**, with **53 genes/probe groups having duplicates**.
- There are **54 risk-associated** and **46 protective-associated** genes.
- **8 genes have FDR ≤ 0.01**, and **71 have FDR ≤ 0.05**.
- Direction conflicts are explicitly reported for **DCBLD2** and **BCL2L14**, and several probe/group labels combine multiple loci or non-gene probe identifiers.
- The retrieved pathway and network records were not recomputed from the table and are **contextual annotations, not new statistical tests**.
- **External/independent statistical validation was not performed**: no independent-cohort HR, P value, FDR, endpoint, or fitted multivariable model was supplied.

Thus, the strongest conclusions are prognostic associations in the **input/uploaded cohort**. Mechanistic and translational interpretations below are hypotheses supported to varying degrees by pathway, tissue, network, disease, and literature evidence.

## 1. Overall biological interpretation

The prognostic profile is consistent with several partially connected features of colorectal cancer biology:

1. **An adverse stromal, extracellular-matrix, adhesion, and motility state**, represented by risk-associated **INHBB, DCBLD2, ITGBL1, TPM4, PTPN14, ABL2, NIN, NT5E, and MSLN**.
2. **Loss or reduction of intestinal epithelial differentiation**, reflected by protective associations for **CDX2**, **MYO5B**, and, more weakly by FDR, **CDX1** and **LGALS4**.
3. **A metabolic and mitochondrial program associated with better OS**, including protective **GLYCTK, CS, ILVBL, MCCC2, ASL, NDUFA9, ATP23, COA3, and OGDHL**.
4. **Immune and extracellular-signaling differences**, including risk-associated **NT5E** and protective-associated **LGALS9, CCL15, TAPBPL, and CCDC134**, although the directionally mixed pattern is compatible with differences in immune-cell composition rather than a single immune mechanism.
5. **Cytoskeletal and microtubule organization**, with risk associations for **TPM4, NIN, MAP1B, ABL2, LRCH8A, and GJB6**.

The most coherent interpretation is therefore a survival-associated contrast between tumors with preserved epithelial/metabolic differentiation and tumors with more adverse stromal-remodeling, motility, and extracellular-signaling features. This remains an association-level interpretation; the data do not establish that any gene causes poor or favorable survival.

## 2. Core biological programs

### Program 1 — Activin/TGF-β-like stromal remodeling and invasive extracellular signaling

- **Association:** Predominantly risk-associated.
- **Major genes:** **INHBB** HR **1.4332849**, FDR **0.0010931622**; **DCBLD2** HR **1.4080371**, FDR **0.0086471166**; **ITGBL1** HR **1.2990091**, FDR **0.030609537**; **PTPN14** HR **1.3616616**, FDR **0.025013259**; **ADAMTS18** HR **1.26342**, FDR **0.046809377**; **MSLN** HR **1.3129539**, FDR **0.045071312**.
- **Relevant standardized pathway:** TGF-β/activin signaling and extracellular-matrix organization are the most biologically appropriate pathway concepts. The supplied batch annotations also include **regulation of phospholipase C activity (GO:1900274)**, which is compatible with extracellular receptor signaling but is not specific for this program.
- **Interpretation:** Multiple risk-associated genes point toward altered extracellular signaling, matrix interaction, and tissue remodeling rather than a single-gene effect. **INHBB** is particularly notable because its association is among the strongest in the table, and a question-specific literature record reports that high INHBB expression in colorectal cancer is associated with poor prognosis and malignant phenotypes (**Europe PMC: 41992239**). This is concordant biological context, not independent statistical replication of the supplied HR.
- **Evidence strength:** **Moderate for a prognostic program; strongest for INHBB.**
- **Limitations:** No formal pathway enrichment statistic for this specific gene set was supplied. Some genes may reflect stromal abundance, tumor purity, stage, or desmoplastic composition. The direction conflict reported for **DCBLD2** reduces confidence in its probe-level interpretation.

### Program 2 — Intestinal epithelial differentiation and epithelial organization

- **Association:** Protective-associated overall.
- **Major genes:** **CDX2** HR **0.74776163**, FDR **0.035501926**; **MYO5B** HR **0.74832371**, FDR **0.028227398**; **LGALS4** HR **0.77119484**, FDR **0.051227162**; **CDX1** HR **0.78085163**, FDR **0.05734561**; **RAB11FIP4** HR **0.73605165**, FDR **0.032940997**.
- **Relevant standardized pathway:** Intestinal epithelial differentiation, epithelial cell polarity, and apical vesicle trafficking are the most appropriate concepts. These genes do not by themselves establish a statistically enriched pathway.
- **Interpretation:** The coordinated protective direction of **CDX2**, **MYO5B**, **RAB11FIP4**, and related epithelial genes is compatible with tumors retaining more differentiated intestinal epithelial features and organized trafficking/polarity. The literature record reports that **CDX2 inhibits colon cancer proliferation and tumor formation through suppression of Wnt/β-catenin signaling** (**PMID: 30631044**), providing mechanistic plausibility for its protective association.
- **Evidence strength:** **Moderate for a differentiation-related hypothesis.**
- **Limitations:** **CDX1** and **LGALS4** do not meet FDR ≤ 0.05 in the supplied table, and preserved differentiation may be a marker of lower stage or lower tumor aggressiveness rather than a causal protective mechanism.

### Program 3 — Mitochondrial and central-carbon metabolism

- **Association:** Predominantly protective-associated.
- **Major genes:** **ATP23** HR **0.68848836**, FDR **0.0066355753**; **NDUFA9** HR **0.68863259**, FDR **0.0086471166**; **GLYCTK** HR **0.70929051**, FDR **0.020341929**; **ILVBL** HR **0.72456474**, FDR **0.032940997**; **MCCC2** HR **0.7389587**, FDR **0.028227398**; **ASL** HR **0.7386697**, FDR **0.035501926**; **CS** HR **0.75447917**, FDR **0.038754165**; **COA3** HR **0.74374187**, FDR **0.043364769**; **OGDHL** HR **0.68584556**, FDR **0.074429916**.
- **Relevant standardized pathway:** Reactome/KEGG concepts related to mitochondrial respiratory-chain function, the citric-acid cycle, amino-acid metabolism, and glyoxylate/dicarboxylate metabolism are relevant.
- **Interpretation:** Several mitochondrial and metabolic genes show HRs around **0.69–0.75**, suggesting that higher expression of a coordinated metabolic state is associated with lower hazard in this dataset.
- **Evidence strength:** **Moderate for a metabolic prognostic signature**, including two of the eight FDR ≤ 0.01 results.
- **Limitations:** This does not prove that oxidative metabolism is tumor-suppressive. Metabolic expression can reflect epithelial differentiation, tumor purity, hypoxia, nutrient availability, or cellular composition. The risk-associated **SLC2A3** HR **1.2812788**, FDR **0.07217316**, also suggests heterogeneous glucose-stress biology.

### Program 4 — Cytoskeletal organization, cell adhesion, and migration

- **Association:** Predominantly risk-associated.
- **Major genes:** **TPM4** HR **1.3635104**, FDR **0.0089096897**; **ABL2** HR **1.3012167**, FDR **0.027572137**; **NIN** HR **1.345184**, FDR **0.028227398**; **MAP1B** HR **1.3274716**, FDR **0.047203854**; **LRRC8A** HR **1.3763533**, FDR **0.025013259**; **GJB6** HR **1.2903407**, FDR **0.039377731**; **LRCH3** HR **1.3408832**, FDR **0.040615485**.
- **Relevant standardized pathway:** The supplied annotations include **microtubule anchoring at the microtubule-organizing center (GO:0072393)** and **regulation of T-cell migration (GO:2000404)**.
- **Interpretation:** The combination of actin-associated **TPM4**, microtubule-organizing-center-associated **NIN**, microtubule-associated **MAP1B**, and signaling/adhesion-associated **ABL2** is compatible with altered cell shape, adhesion, trafficking, and motility.
- **Evidence strength:** **Moderate for a cytoskeletal/migration hypothesis.**
- **Limitations:** The available network evidence does not establish a direct physical complex among these genes. No invasion assay, metastasis endpoint, or independent survival statistic was supplied.

### Program 5 — Immune–extracellular signaling and purinergic regulation

- **Association:** Mixed, with **NT5E** risk-associated and several immune-related genes protective-associated.
- **Major genes:** **NT5E** HR **1.312982**, FDR **0.039390717**; **LGALS9** HR **0.75332171**, FDR **0.042038752**; **CCL15** HR **0.75282151**, FDR **0.035501926**; **TAPBPL** HR **0.71101448**, FDR **0.019210192**; **CCDC134** HR **0.71188623**, FDR **0.025159126**.
- **Relevant standardized pathway:** Regulation of T-cell migration (**GO:2000404**) and extracellular purine metabolism/adenosine signaling are appropriate concepts.
- **Interpretation:** Risk-associated **NT5E/CD73** may indicate an extracellular adenosine-producing, immunoregulatory environment. However, protective associations for **LGALS9**, **CCL15**, **TAPBPL**, and **CCDC134** indicate that the immune signal is not a uniform “immune suppression” program.
- **Evidence strength:** **Exploratory to moderate**, strongest for the NT5E association itself.
- **Limitations:** These transcripts may predominantly reflect immune-cell composition rather than tumor-cell biology. The mixed directions make a single immune mechanism insufficiently established.

## 3. Key genes and interaction modules

1. **INHBB — risk-associated; HR 1.4332849, FDR 0.0010931622.**
2. **TPM4 — risk-associated; HR 1.3635104, FDR 0.0089096897.**
3. **DCBLD2 — risk-associated representative HR 1.4080371, FDR 0.0086471166, but direction-conflict across retained rows.**
4. **ITGBL1 — risk-associated; HR 1.2990091, FDR 0.030609537.**
5. **CDX2 — protective-associated; HR 0.74776163, FDR 0.035501926.**
6. **GLYCTK — protective-associated; HR 0.70929051, FDR 0.020341929.**
7. **ATP23/NDUFA9 mitochondrial module — both protective-associated; HR 0.68848836 and 0.68863259, FDR 0.0066355753 and 0.0086471166, respectively.**
8. **NT5E — risk-associated; HR 1.312982, FDR 0.039390717.**
9. **MIR31HG/ZEB1-AS1 long noncoding-RNA module — both risk-associated; HR 1.3093772 and 1.3719515, FDR 0.0066355753 and 0.0086471166, respectively.**
10. **LRCH1/LRCH3 network module — both risk-associated; LRCH1 HR 1.336615, FDR 0.05987699; LRCH3 HR 1.3408832, FDR 0.040615485.**

These are **input/uploaded-cohort** statistics. No HR, P value, or FDR from an **external/independent** validation cohort is asserted here.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=22, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: OpenAI / gpt-5.6-luna

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
